Alvimopan

Postoperative ileus is a common complication of abdominal surgery, which not only prolongs the hospitalization period of patients, but also may induce secondary risks such as intestinal adhesion and infection. As a peripheral μ-opioid receptor antagonist, alvimopan provides a precise intervention pathway for the recovery of intestinal function in such patients. It can selectively block peripheral opioid receptors in the gastrointestinal tract without affecting the analgesic effect of central opioid drugs. It is approved to accelerate the functional recovery of the upper and lower gastrointestinal tract after surgery, and is applicable to adult patients who undergo abdominal surgery and require opioid analgesia, filling the clinical gap of "balance between analgesia and gastrointestinal recovery" in postoperative intestinal management.

The global alvimopan market size was approximately USD 420 million in 2023, and is expected to maintain a compound annual growth rate of 6.8% from 2024 to 2030. The growth momentum mainly comes from the steady increase in the volume of surgical procedures and the popularization of the concept of enhanced recovery after surgery (ERAS). In terms of competitive landscape, the original research product has long occupied the major market share. At present, no generic drugs from local enterprises have been approved for marketing in China, and the relevant domestic clinical needs have not been fully met.

The original research enterprise of alvimopan is GlaxoSmithKline, with the trade name Entereg. Its core compound patent in the United States expired in 2016, and the compound patent in China expired in 2017. The dosage form approved for the original research product is capsule, with a specification of 12mg. It has been included in the FDA Reference Listed Drug Catalog, but has not yet been included in the *Chinese Catalog of Chemical Drugs*. At present, there is no alvimopan preparation product approved for marketing in China, and there is no publicized alvimopan API registration number with A status on the CDE API registration platform. (Data as of September 2025, please refer to the official CDE website for the latest information)

CATO can provide a full set of alvimopan impurity reference standards, most of which are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. The products fully comply with the compliance requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, and can provide stable reference standard support for the qualitative and quantitative analysis of impurities in the stages of drug development and quality research.